Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Upadacitinib |
Synonyms | |
Therapy Description |
Rinvoq (upadacitinib) is an inhibitor of JAK1 and JAK3, which may lead to decreased cell proliferation (PMID: 31976485). Rinvoq (upadacitinib) is FDA approved for rheumatoid arthritis (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Upadacitinib | Rinvoq | ABT 494|ABT-494 | JAK1 Inhibitor 9 JAK3 Inhibitor 6 | Rinvoq (upadacitinib) is an inhibitor of JAK1 and JAK3, which may lead to decreased cell proliferation (PMID: 31976485). Rinvoq (upadacitinib) is FDA approved for rheumatoid arthritis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 L875H | hematologic cancer | resistant | Upadacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L875H demonstrated resistance to treatment with Rinvoq (upadacitinib) in culture (PMID: 31976485). | 31976485 |
JAK3 L857Q | hematologic cancer | sensitive | Upadacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L857Q were sensitive to treatment with Rinvoq (upadacitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|